Forfivo Tablet, Film Coated, Extended Release
NDC Package 24979-247-06
Package Information
Forfivo (bupropion hydrochloride) tablets is a medication used to treat depression. This formulation utilizes a tablet, film coated, extended release delivery system. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 24979-247 and is authorized under FDA application NDA022497.
Identification & Billing
- RxCUI: 1232585 - buPROPion HCl 450 MG 24HR Extended Release Oral Tablet
- RxCUI: 1232585 - 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet
- RxCUI: 1232585 - bupropion hydrochloride 450 MG 24 HR Extended Release Oral Tablet
- RxCUI: 1232591 - Forfivo XL 450 MG 24HR Extended Release Oral Tablet
- RxCUI: 1232591 - 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet [Forfivo]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 24979 - Upsher-smith Laboratories, Llc
- 24979-247 - Forfivo
- 24979-247-06 - 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
- 24979-247 - Forfivo
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 24979-247-06 identifies a specific commercial package of 30 tablet, film coated, extended release in 1 bottle of Forfivo XL, a human prescription drug labeled by Upsher-smith Laboratories, Llc. This tablet, film coated, extended release is formulated for oral use and contains bupropion hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Llc on December 15, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat depression. It may also be used to prevent seasonal affective disorder (SAD), a type of depression that occurs each year at the same time (for example, during winter). This medication can improve your mood and feelings of well-being. It may work by restoring the balance of certain natural substances (dopamine, norepinephrine) in the brain.
How is this Upsher-smith Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 24979024706. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.